A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Caroline C Øhrstrøm, Dorte L Hansen, Urd Lynge Kielgast, Bolette Hartmann, Jens Juul Holst, Dorte Worm

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

OriginalsprogEngelsk
Sider (fra-til)1605-1610
Antal sider6
TidsskriftObesity Surgery
Vol/bind30
Udgave nummer4
Tidlig onlinedato10 nov. 2019
DOI
StatusUdgivet - apr. 2020

Fingeraftryk

Udforsk hvilke forskningsemner 'A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals' indeholder.

Citationsformater